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the National Hospital Ambulatory Medical Care Survey
(NHAMCS) data from 1993 through 2004. Both are national
probability surveys of visits to ofﬁce-based physicians and ambu-
latory services in hospital emergency and outpatient departments
and provide weights to obtain nationally representative esti-
mates. Seventy-six different medicines of herbal origin were iden-
tiﬁed based on their generic codes and the visits in which they
were prescribed were calculated for each year. RESULTS: In
1993, of the total 1.6 billion NAMCS & NHAMCS visits, her-
bal medication was prescribed in 0.14% ambulatory visits
[2,328,901 (95% C.I.: 2,298,097–2,359,705)]. This proportion
increased to 0.26% in 2004 or 2,883,006 visits (95% C.I.:
2,821,529–2,944,483) of the total 1.1 billion visits. The ﬁve
most commonly prescribed medications were Psyllium, Senna,
Garlic, Ginkgo and Ipecac. Forty-nine of the total seventy-six
study drugs were never prescribed during a physician visit
throughout the study period. CONCLUSION: The trend of pre-
scribing of herbal medications during ofﬁce-based physician
visits has risen over the past decade but is limited to selected
herbal products and is not widepread.
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OBJECTIVES: To identify cases of polypharmacy (PF) and to
describe their social and clinical characteristics, satisfaction and
costs in elderly patients who attended Family Medicine health
care services at the Mexican Institute of Social Security (IMSS).
METHODS: Cross sectional study in 260 elders (°Y´ 65 years
old) who attended a Family Medicine facility at the IMSS in
Mexico City. A survey and a concurrent review of medical
records were performed to identify characteristics of drug pre-
scription and patients’ satisfaction in the previous 3 months. The
WHO deﬁnition of polypharmacy was used to classify this pre-
scribing pattern: simultaneously consumption of more than 3
drugs. Costs were estimated from an institutional perspective
and are expressed in US dollars (USD). RESULTS: Mean age was
71 years (6.9 SD), 60.8% were female, 15.8% illiterate, 53.5%
married, 10.4% single and 35.4% widow/widower. A high per-
centage (86.2%) reported having a chronic disease; the main
problems were hypertension (57.7%), diabetes (35.4%), and
sleep problems (35.4%). Satisfaction with medication was: very
high 56.9%, high 28.5%, mild 8.1%, low 1.2%, and very low
0.8%. Drug mean cost per patient was 6.6 USD (per month) with
a maximum of 61.8 USD. Prescription of 3 drugs at the same
time was reported in 64.2% and polypharmacy in 49.2% CON-
CLUSION: Our study found that polypharmacy was a common
prescribing pattern in Family Medicine services. Prescription of
3 drugs at the same time and polypharmacy might lead to an
important proportion of health care costs. Among the elderly
population the proportion of chronic conditions was high, as
was satisfaction with drug treatment. It is possible that there is
a trade-off between improvement of symptoms and adverse side
effects of drugs; therefore it would be necessary to research the
quality of life, drug prescription and its justiﬁcation in these
patients.
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OBJECTIVES: The purpose of this study was to determine the
impact of copayment differential between tier-one and tier-two
medications on the generic dispensing rates. METHODS: A pre-
post study design with control group analysis was conducted to
investigate the effect of a changing copayment structure on the
Generic Dispensing Rate (GDR). Clients that changed their
copayment structure during the 2006 ﬁscal year were identiﬁed.
Data from ﬁve clients from pharmacy claims database main-
tained by a large pharmacy beneﬁt manager (PBM) were col-
lected. Study clients had one of the three effective dates during
which they changed their copayment structures: January 1, 2006;
July 1, 2006; or October 1, 2006. Two clients that did not change
their copayment in 2006 were included as control groups. Dif-
ferences in the copayment amount and percentage change in
GDR for pre and post periods were computed and compared
using independent t-tests. In addition, an adjusted GDR was cal-
culated by subtracting a nominal increase in the control groups
from each of the study groups. RESULTS: Clients that changed
their copayment structure in January 1, 2006 reported a mean
GDR increase of 2.36% with a mean $8.32 increase in their
copayment amount (p-value < 0.05). Similarly, clients who
changed their copayment structure in July 1, 2006 demonstrated
a mean GDR increase of 4.06% with a mean $9.13 increase in
their copayment amount (p-value < 0.05). While clients that
changed their copayment structure during October 1, 2006
period showed a net increase in GDR of 2.7% with a $3.36
increase in copayment amount. Such changes were also found to
be statistically signiﬁcant when compared to the changes
reported by the control clients. CONCLUSION: Increasing the
copayment amount between tier-one and tier-two demonstrated
a positive impact on GDR thereby translating into potential
savings for the clients.
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OBJECTIVES: To compare generic dispensing rate (GDR)
among 30-day retail program, mandatory 90-day retail program
and voluntary 90-day retail program. METHODS: This analy-
sis was conducted using pharmacy claims data from a pharmacy
beneﬁt manager (PBM). Patients who were new to either Ace-
Inhibitor, statins or SSRIs in March-May 2005 were identiﬁed
and followed-up for a period of 12-month to measure their
GDR. Patients had retail 30-day supply only during the study
period were included in 30-day retail program, patients had
mandatory 90-day supply during the study period were in
mandatory 90-day retail program, and similarly, patients had
voluntary 90-day supply were in voluntary 90-day retail
program. GDR was measured by claim level as well as patient
level, which was the number of generic claims and/or patients
using generic medications divided by total number of claims
and/or total patients. All claims were normalized to a 30-day
supply. RESULTS: About 4678 claims and 907 patients in 30-
day retail program, 1438 claims and 138 patients in mandatory
90-day retail program, 5136 claims and 538 patients in volun-
tary 90-day retail program. GDR was found to be relatively
higher in voluntary 90-day retail program (47.65%, 47.77%),
